Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich's Q2 Sales Climb 14.4 Percent

NEW YORK (GenomeWeb News) – Sigma-Aldrich reported after the close of the market on Tuesday that its second-quarter revenues rose 14.4 percent, or 7.1 percent excluding the impact of currency translation.
The St. Louis-based research products and chemicals company brought in revenues of $580.7 million for the three-month period ended June 30 compared to revenues of $507.5 million for the second quarter of 2007.
The firm’s Research Essentials unit posted sales growth of 13.5 percent to $109.4 million; its Research Specialties unit had 16.8 percent revenue growth to $214.5 million; its Research Biotech unit posted sales growth of 17.6 percent to $86.4 million; and the SAFC unit had sales of $170.4 million, up 10.7 percent year over year.
Sigma-Aldrich’s net income for the second quarter was $90.8 million, or $.70 per share, up 13.9 percent from last year’s Q2 profit of $79.7 million, or $.60 per share.
The firm’s R&D expenses increased 10.3 percent to $16 million from $14.5 million, and its SG&A costs rose 10.9 percent to $144.5 million from $130.3 million.
Sigma-Aldrich finished the quarter with $240.3 million in cash and cash equivalents.
The company is targeting full-year 2008 organic sales growth of 7 percent and earnings per share of between $2.62 and $2.72.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.